Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

NCT07070479 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

208

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: Ivonescimab
DRUG: Nimotuzumab
DRUG: Irinotecan liposome
DRUG: S-1
DRUG: Mitoxantrone Hydrochloride Liposome
DRUG: PD-1 Inhibitors

Sponsor

Ming-Yuan Chen